SecBot SecBot
SECBOTREPLAY Home › Report › IOVA

IOVA · Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase,…

IOVANCE BIOTHERAPEUTICS, INC. · 8-K filed Aug 6, 2026 at 07:05 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 6, 2026 at 07:05 ET

Iovance reported record Q2 2026 revenue of ~$99.3M, a 66% YoY increase, driven by U.S. Amtagvi revenue of ~$91M. Gross margin improved to 56%, and the net loss narrowed to -$0.11/share from -$0.33/share YoY. The company is reviewing its FY26 revenue guidance of $350M-$370M for a potential raise, while advancing its pipeline with FDA Fast Track Designation for lifileucel in soft tissue sarcomas.

  • Total product revenue of ~$99.3M, up 66% YoY from ~$59.95M in Q2 2025.
  • U.S. Amtagvi revenue reached ~$91M, up 40% from Q4 2025.
  • Gross margin improved to 56% from 41% in Q1 2026.
  • Net loss per share narrowed to -$0.11 from -$0.33 YoY, beating consensus of -$0.13.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access